The Conversation (0)
BioVie filed an application for patent coverage of their new drug candidate BIV201 in Japan.
BioVie (OTCQB:BIVI) filed an application for patent coverage of their new drug candidate BIV201 in Japan.
As quoted in the press release:
This follows the recent issuance of US Patent No. 9,655,945 for the use of BIV201 to treat this medical condition. The Company is pursuing an approach known as the “patent prosecution highway” in order to seek an expedited patent approval in Japan, which may take less than one year.
BioVie is an emerging leader in the development of drug therapies for ascites and other life-threatening complications of advanced liver cirrhosis. The Company is about to begin a mid-stage (Phase 2a) clinical trial in the US administering BIV201 to patients with ascites. The active agent in BIV201, terlipressin, is approved for use in about 40 countries for the treatment of related complications of advanced liver cirrhosis, but is not available in the US or Japan.
Click here to read the full press release.
Source: www.marketwired.com
